United Therapeutics Corp
NASDAQ:UTHR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
210.76
410
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
United Therapeutics Corp
United Therapeutics Corp
Other Long-Term Assets
United Therapeutics Corp
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Other Long-Term Assets
$574.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$8.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
44%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$7.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
23%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$10.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
43%
|
CAGR 10-Years
21%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$3.2B
|
CAGR 3-Years
49%
|
CAGR 5-Years
17%
|
CAGR 10-Years
95%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
70%
|
CAGR 5-Years
34%
|
CAGR 10-Years
31%
|
|
United Therapeutics Corp
Glance View
In the landscape of biotechnology, United Therapeutics Corp. has crafted a compelling narrative centered around innovation and transformation, principally targeting life-threatening conditions. Founded in 1996 by Martine Rothblatt, the company's inception was motivated by the urgent need to find solutions for her daughter's rare disease, pulmonary arterial hypertension (PAH). Over the years, United Therapeutics has stayed true to its pioneering ethos, focusing on creating and commercializing unique therapies that address the needs of patients with severe and often unmet health challenges. The core of its operations revolves around developing drugs that enhance survival and quality of life for individuals afflicted by PAH and other similar illnesses. Such dedication to research and pharmaceutical development has fostered a robust product pipeline, including therapeutics like Remodulin and Tyvaso, which play pivotal roles in the company's revenue generation. Financially, United Therapeutics sustains its momentum through a blend of strong patent portfolios and strategic market positioning, ensuring both competitive advantage and an ongoing revenue stream. By maintaining a keen focus on specific niches within the biotechnology sector, the company minimizes competition while maximizing the impact of its therapeutic solutions. Its business model thrives on the supply of specialized medications, which, given their critical nature, command premium pricing. Yet, United Therapeutics doesn’t solely pivot around drug sales; it is deeply invested in the future of medicine, notably venturing into areas like organ manufacturing and xenotransplantation, where it seeks to address broader and more complex health challenges. Through a blend of innovation, strategic partnerships, and diversification into emerging medical fields, United Therapeutics continues to cement its reputation as a leader in biotechnological advancement.
See Also
What is United Therapeutics Corp's Other Long-Term Assets?
Other Long-Term Assets
574.5m
USD
Based on the financial report for Sep 30, 2024, United Therapeutics Corp's Other Long-Term Assets amounts to 574.5m USD.
What is United Therapeutics Corp's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
7%
Over the last year, the Other Long-Term Assets growth was 31%. The average annual Other Long-Term Assets growth rates for United Therapeutics Corp have been 14% over the past three years , 3% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
